Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Takahashi A, Nomoto H, Yokoyama H, Yokozeki K, Furusawa S, Oe Y, Kameda R, Kawata S, Miyoshi A, Nagai S, Miya A, Kameda H, Nakamura A, Atsumi T; MEGMI study group. Takahashi A, et al. Among authors: miya a. Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39726204
Management of thyroid tumors diagnosed cytologically as follicular neoplasms in a high-volume center: utility of a scoring system using serum thyroglobulin level, tumor size, ultrasound testing, and cytological diagnosis.
Ito Y, Kawakami M, Hirokawa M, Yamamoto M, Kihara M, Onoda N, Miya A, Miyauchi A, Akamizu T. Ito Y, et al. Among authors: miya a. Endocr J. 2024 Oct 29. doi: 10.1507/endocrj.EJ24-0364. Online ahead of print. Endocr J. 2024. PMID: 39477488 Free article.
A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
Takahashi A, Nomoto H, Onishi K, Manda S, Miya A, Kameda H, Nakamura A, Atsumi T. Takahashi A, et al. Among authors: miya a. Diabetes Obes Metab. 2024 Aug;26(8):3471-3474. doi: 10.1111/dom.15639. Epub 2024 May 3. Diabetes Obes Metab. 2024. PMID: 38699794 Clinical Trial. No abstract available.
322 results